One of the more controversial and critical parts of Bayer’s $10 billion-plus settlements of Roundup cases last week is a separate deal to resolve future claims that—because it comes in a class action—faces judicial scrutiny and potential objections that may unravel the agreement.

The class action settlement, which includes a $1.1 billion fund, is a key part of Bayer’s strategy to cap its subsidiary Monsanto’s Roundup litigation while keeping its product on store shelves.